drugset / Trial / NCT01111123

Ammonium Lactate Lotion 12% (Lac-hydrin®) and Halobetasol Propionate Ointment 0.05% (Ultravate®) in the Treatment and Maintenance of Psoriasis

NCT01111123

Phase 4 Completed 55 enrolled Icahn School of Medicine at Mount Sinai
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether the combinational use of ammonium lactate lotion 12% (Lac-Hydrin) and halobetasol propionate ointment 0.05% (Ultravate) is safe and effective in the initial treatment and long-term maintenance of psoriasis. Patients will use both medications continuously for two weeks and those who obtain a good improvement based on investigator clinical assessments will be randomized to Lac-Hydrin lotion twice daily every day with placebo ointment or Ultravate ointment twice daily on weekends only for up to 24 more weeks.

Timeline

Start
2009-01
Primary completion
2010-03
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ammonium Lactate Small molecule 12 % Topical
Comparator halobetasol propionate Small molecule 0.05 % Topical

Indications